-
How does the differentiation of the five new-generation BTK inhibitors that have been approved globally reflect?
Time of Update: 2021-09-04
In addition to improving the specificity of covalent irreversible BTK inhibitors, the development of new reversible BTK inhibitors to overcome drug resistance, a new generation of products that can cross the blood-brain barrier, BTK targeted protein degradation agents, etc.
-
Quotations of 34 large-species collection pharmaceutical companies started
Time of Update: 2021-09-04
According to the centralized procurement rules, the company's quotation shall not be higher than the current minimum bid-winning price of the company in the two provinces of Gansu and Shaanxi .
-
PD-1 antibody "partner" TIL therapy challenges advanced lung cancer
Time of Update: 2021-09-04
Researchers at the Moffitt Cancer Center in the United States initiated an evaluation of the PD-1 antibody nivolumab (trade name: Odivo) in combination with tumor infiltrating lymphocytes (TIL) for the treatment of advanced non-small cell lung cancer (NSCLS) Phase I clinical trial .
-
National centralized procurement of high-value consumables for artificial joints will be fully launched on September 14
Time of Update: 2021-09-04
Price limit rules for four types of products: Various reporting requirements Eligibility for declaration: Reporting companies to have achieved this focus with the amount of purchased product legally qualified medical device registrant ( proxy person), reporting companies must clearly serves regional, and promised each product system corresponds to all models for the procurement to meet the regional purchasing demand cycle .
-
On Roxastat in the vortex of controversy
Time of Update: 2021-09-04
Roxastat has also become the first innovative drug to be marketed in the world for the first time in China, which has aroused global attention; on August 16, 2019, Roxastat was approved to treat non-dialysis patients with renal anemia through the priority review process .
-
Hengrui semi-annual report domestic and international research and development pipeline dominates the screen!
Time of Update: 2021-09-04
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization .
-
Why is Pfizer's US$2.26 billion "Don't Eat Me" signal channel favored by many major pharmaceutical companies?
Time of Update: 2021-09-04
26 billion to acquire Trillium and obtain two research therapies that block the CD47-SIRPα signaling pathway .
-
Chinese companies independently researched and developed new crown + A and B stream joint detection kits approved for listing
Time of Update: 2021-09-04
The new crown combined influenza A and B virus nucleic acid detection kit independently developed and produced by Chinese biomedical science and technology enterprises has been approved by the National Medical Products Administration.
-
CDE Yang Zhimin, Xie Songmei: Drug review promotes the development of pediatric drugs through multiple channels, and product reviews are gradually increasing!
Time of Update: 2021-09-04
She said: “Through early communication in clinical research and development, we recommend that the original research company conduct clinical trials in China as soon as possible to provide data support for scientific decision-making in drug review .
-
What kind of industry signal does Hengrui adjust its sales team to release?
Time of Update: 2021-09-04
Author: ProbioticsRecently, Hengrui Medicine held an extraordinary general meeting of shareholders. Hengrui Chairman Sun Piaoyang announced the abolition and adjustment plan for the sales team, which
-
CDE Director Kong Fanpu: Innovative drug review set a new record, and the international drug review track accelerated
Time of Update: 2021-09-04
With the year-on-year increase in the number of drug registration application tasks and the high technical content of the declared varieties, the overall completion rate of the innovative drug-related tasks of the Center for Drug Evaluation exceeded 90% within the time limit .
-
Fosun Pharma Announces 2021 Interim Results, Innovation Results Continue to Land, International Operation Capability Further Improved
Time of Update: 2021-09-04
73%;· The joint venture Fosun Kate’s Yi Kai Da is the first CAR-T cell therapy product approved for marketing in China;· Fubitai® (mRNA Covid-19 vaccine, BNT162b2) was included in the government vaccination program in Hong Kong and Macau in the first half of the year; and it plans to supply 15 million doses of mRNA Covid-19 vaccine to Taiwan, China .
-
North China Pharmaceuticals has a lower limit!
Time of Update: 2021-09-04
It was once the cradle of the pharmaceutical industry in New China and was known as the “eldest son of medicine” of the Republic. North China Pharmaceuticals, one of the four major pharmaceutical fac
-
News analysis: Where did you go to find the new crown drug?
Time of Update: 2021-09-04
"Speed type" contestant-biological macromolecular drugs At present, the rapid progress in global research and development is biomacromolecule drugs, mainly antibodies, including single-drug monoclonal antibodies and combined use of "antibody cocktail therapy" .
-
Blockbuster drug with patent expiration in the next 10 years (12)-Disumab
Time of Update: 2021-09-04
In the absence of a large number of patent exclusivity losses in recent years, the company is expected to enter a growth phase driven by new drugs, including the migraine drug Aimovig (erenumab) and the newly approved anti-cancer drug Lumakras (sotorasib) .
-
There is not much time left for insulin!
Time of Update: 2021-09-04
In the end, this special procurement with a total purchase volume of 1,705,700 units led to a 43% reduction in the unit price of some successful insulin drugs .
-
Huiyu's first new drug is coming to grab 6 billion cardiovascular varieties
Time of Update: 2021-09-04
0 Chinese Drug Evaluation Database At present, in addition to Huiyu’s clinical application of new drugs, Livzon has already submitted an application for the generic listing of 4 types of butylphthalide sodium chloride injection and has been approved for clinical use.
-
In July, 136 product regulations passed the consistency evaluation of generic drugs
Time of Update: 2021-09-04
(Contributed by Yaorong Circle) According to data from the National Medical Products Administration on August 25th, in July this year, the Center for Drug Evaluation (CDE) of the National Medical Products Administration undertook 80 applications for the consistency evaluation of generic drugs (calculated by the acceptance number), and 54 varieties were accepted.
-
Well-known pharmaceutical companies responded: no layoffs
Time of Update: 2021-09-04
Mengdi China further stated that, judging from the feedback currently received by the company's human resources department, the overall feedback from employees who have been included in the talent retention program is positive-some of the previous information was not accurate .
-
Johnson & Johnson/Theravance ulcerative colitis drug idencitinib failed Phase II clinical trial
Time of Update: 2021-09-04
A few days ago, because the drug's Phase 2 dose exploration study in ulcerative colitis failed to reach the primary endpoint, the outside world has doubts about the prospects of this JAK inhibitor in indications including ulcerative colitis .
